PL426731A1 - - Google Patents

Info

Publication number
PL426731A1
PL426731A1 PL42673118A PL42673118A PL426731A1 PL 426731 A1 PL426731 A1 PL 426731A1 PL 42673118 A PL42673118 A PL 42673118A PL 42673118 A PL42673118 A PL 42673118A PL 426731 A1 PL426731 A1 PL 426731A1
Authority
PL
Poland
Prior art keywords
compound
derivative
glycoconjugate
methotrexate
innovative
Prior art date
Application number
PL42673118A
Other languages
English (en)
Other versions
PL242529B1 (pl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to PL426731A priority Critical patent/PL242529B1/pl
Publication of PL426731A1 publication Critical patent/PL426731A1/pl
Publication of PL242529B1 publication Critical patent/PL242529B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest związek będący glikokoniugatową pochodną metotreksatu i glukozy, jak również sposób syntezy tego związku. Nowa pochodna wykazuje działanie przeciwnowotworowe i znajduje zastosowanie w przemyśle farmaceutycznym i weterynaryjnym, jako element innowacyjnej i selektywnej terapii przeciwnowotworowej.
PL426731A 2018-08-20 2018-08-20 Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania PL242529B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL426731A PL242529B1 (pl) 2018-08-20 2018-08-20 Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL426731A PL242529B1 (pl) 2018-08-20 2018-08-20 Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania

Publications (2)

Publication Number Publication Date
PL426731A1 true PL426731A1 (pl) 2020-02-24
PL242529B1 PL242529B1 (pl) 2023-03-06

Family

ID=84701908

Family Applications (1)

Application Number Title Priority Date Filing Date
PL426731A PL242529B1 (pl) 2018-08-20 2018-08-20 Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania

Country Status (1)

Country Link
PL (1) PL242529B1 (pl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022260546A1 (en) * 2021-06-11 2022-12-15 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu A glucose-methotrexate conjugate for use in preventing or treating autoimmune diseases
WO2022260545A1 (en) * 2021-06-11 2022-12-15 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Synthesis of a novel glucose-conjugated methotrexate and its application for the treatment and prevention of neoplasms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022260546A1 (en) * 2021-06-11 2022-12-15 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu A glucose-methotrexate conjugate for use in preventing or treating autoimmune diseases
WO2022260545A1 (en) * 2021-06-11 2022-12-15 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Synthesis of a novel glucose-conjugated methotrexate and its application for the treatment and prevention of neoplasms

Also Published As

Publication number Publication date
PL242529B1 (pl) 2023-03-06

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
DK3804716T3 (da) Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MY200925A (en) Peptide Amide Compound and Preparation Method and Medical use Thereof
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
BR112017008976A2 (pt) ?composição, métodos de aumento da viscosidade de composições aquosas, de tratamento de material, de produção de dextrano e reação enzimática?
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
EP4628094A3 (en) BAFF-R ANTIBODIES AND THEIR USES
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
MX380032B (es) Sintesis de indazoles.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
MX382347B (es) Derivados de piridincarboxamida, su método de preparación y sus usos farmacéuticos.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
BR112018004310A2 (pt) derivados de espinosina e método de preparação
EP3339307A8 (en) Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
MX2018010801A (es) Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos.
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
MX2017014987A (es) Composiciones farmaceuticas.